Related by context. All words. (Click for frequent words.) 67 dyspnoea 66 pruritus 65 nasopharyngitis 64 symptom severity 64 rhinorrhea 64 dysuria 64 myalgia 64 leukopenia 64 pyrexia 63 P = .# 63 apnea hypopnea index 62 pruritis 62 leucopenia 62 peripheral edema 62 hypotension 62 hypoxemia 62 NIH CPSI 62 oxycodone CR 62 ≥ 62 COPD exacerbation 62 MADRS score 62 arthralgia 61 4mg/kg 61 confidence interval CI 61 hypokalemia 61 constipation nausea 61 fatigue asthenia 61 apnea hypopnea 61 nasal symptoms 61 febrile neutropenia 61 paresthesias 61 placebo p = 61 abdominal distension 61 CI -#.# 61 pericardial effusion 61 laboratory abnormalities 61 tolvaptan 61 hypophosphatemia 61 ecchymosis 60 bosentan 60 severe exacerbations 60 hypomagnesemia 60 asthenia 60 lopinavir r arm 60 nasal obstruction 60 GERD symptom 60 extrapyramidal symptoms 60 HbA 1c levels 60 nausea photophobia 60 abdominal pain abdominal discomfort 60 subscore 60 SGRQ 60 intermittent claudication 60 tiotropium 60 pleural effusion 60 thrombocytopenia 60 abdominal distention 60 methacholine 60 dysphagia 59 achieved ACR# 59 â ‰ ¥ 59 Psoriasis Area 59 progressive dyspnea 59 Secondary endpoints 59 tirofiban 59 myocardial ischemia 59 syncope 59 asthma exacerbation 59 OAB symptoms 59 paresthesia 59 somnolence fatigue 59 UPDRS 59 solifenacin 59 RLS symptoms 59 epistaxis 59 PaO 2 59 mg BID 59 tolterodine ER 59 nasal itching 59 thromboembolic 59 acutely decompensated congestive heart 59 oxygen desaturation 59 generalized edema 59 hypopneas 59 % CI #.#-#.# [007] 59 NATRECOR R 59 neutropaenia 59 peripheral sensory neuropathy 59 pharyngolaryngeal pain 59 placebo p 59 myalgias 59 Crohn Disease Activity 59 treatment emergent adverse 59 desvenlafaxine succinate 59 arthralgias 59 % CI #.#-#.# [006] 59 nasopharyngitis headache 59 nocturia 58 HRQL 58 lymphopenia 58 postoperatively 58 nausea vomiting headache 58 pulmonary capillary wedge 58 mucosal inflammation 58 p = #.# [002] 58 HRQoL 58 sensory neuropathy 58 myalgia arthralgia 58 nasal symptom 58 p = #.# [004] 58 CSBMs 58 macroalbuminuria 58 alanine aminotransferase 58 hemoptysis 58 p = .# [002] 58 headache nausea fatigue 58 mEq L 58 exacerbations 58 asthma exacerbations 58 dyspareunia 58 PANSS scores 58 elevated lipase 58 IBDQ 58 salmeterol fluticasone 58 diarrhea nausea fatigue 58 systemic corticosteroid 58 epigastric pain 58 SGPT 58 PCWP 58 incidence ≥ 58 neutropenia thrombocytopenia 58 cough wheezing 58 bronchial hyperresponsiveness 58 HDRS 58 plus methotrexate 58 headache nasopharyngitis 58 CSBM 58 receiving ISENTRESS 58 discontinuations due 57 orthostatic hypotension 57 bothersome symptom 57 spontaneous bowel movements 57 phonophobia 57 DAS# [002] 57 QRS duration 57 IBS symptoms 57 conjunctival hyperemia 57 clinically meaningful improvement 57 fluticasone salmeterol 57 Brief Psychiatric 57 nasal congestion 57 diarrhea dyspepsia 57 nonfatal MI 57 mcg BID 57 nonproductive cough 57 Infusion Reactions Severe 57 Montgomery Åsberg Depression 57 highly emetogenic 57 apneic 57 HbA 1c 57 cough dyspnea 57 stomatitis 57 chills fever headache 57 FEV1 57 bradycardia 57 cerebrovascular events 57 claudication 57 rhinitis 57 salmeterol HFA MDI 57 paraesthesia 57 PLMS 57 pentoxifylline 57 ATACAND 57 dizziness nausea diarrhea 57 GERD symptoms 57 pulmonary exacerbation 57 recurrent ischemia 57 WOMAC pain 57 gout flares 57 akinesia 57 erythema 57 gastro oesophageal reflux 57 airflow obstruction 57 mcg QD 57 -#.# ± [002] 57 neutropenia dehydration dyspnea 57 renal insufficiency 57 headache vomiting 57 postdose 57 UPDRS motor 57 nausea constipation 57 CIMZIA TM certolizumab pegol 57 adenotonsillectomy 57 overt nephropathy 57 HAM D# 57 somatic symptoms 57 COPD exacerbations 57 headache abdominal pain 57 abdominal pain flatulence 57 somnolence dizziness 57 paroxysmal 57 Visual Analogue Scale VAS 56 symptomatic VTE 56 dizziness constipation 56 ictal 56 hypopnea 56 ropivacaine 56 pulmonary function 56 hour bronchodilation 56 STN stimulation 56 HBeAg negative patients 56 LVEF 56 dysgeusia 56 CDAI 56 p = NS 56 VIIBRYD 56 frequent awakenings 56 urinary symptoms 56 primary aldosteronism 56 Rating Scale MADRS 56 neurologic symptoms 56 receiving XGEVA 56 EDSS score 56 hypersomnia 56 receiving golimumab 56 RLAI 56 achieved statistical significance 56 β blockers 56 mg QD 56 NATRECOR ® 56 Dyspnea 56 detrusor overactivity 56 atrioventricular block 56 lispro 56 methacholine challenge 56 ADAS cog 56 extrapyramidal disorder 56 PANSS 56 apneas 56 HBeAg seroconversion 56 delayed gastric emptying 56 hematologic adverse 56 daytime sleepiness 56 severe hypoglycemic 56 events AEs 56 chills headache 56 NNT = 56 liver histology 56 episodic migraine 56 HBeAg positive patients 56 Alzheimer Disease Assessment 56 gastrointestinal perforation 56 hematologic toxicity 56 ACTEMRA TM 56 emotional lability 56 YMRS 56 pulmonary arterial 56 detrusor 56 nausea diarrhea 56 sinus tachycardia 56 nicardipine 56 timepoints 56 hypocalcemia 56 asystole 56 Perforomist Inhalation Solution 56 Secondary endpoints included 56 incontinence episodes 56 gastrointestinal symptoms 56 posttreatment 56 x ULN 56 levodopa therapy 56 symptom onset 56 left ventricular systolic 56 Montgomery Asberg Depression 56 NSTEMI 56 subscales 56 elevated serum creatinine 56 nighttime awakenings 56 intraocular inflammation 56 placebo 56 autonomic dysfunction 56 macrovascular events 56 antiemetics 56 postprocedure 56 PREZISTA r arm 55 transaminases 55 mL kg 55 pruritus rash 55 thrombocytopenia neutropenia 55 tapentadol ER 55 HAQ DI 55 rhinoconjunctivitis 55 hyperglycaemia 55 somnolence sedation 55 drowsiness nausea 55 NYHA functional class 55 Index CDAI 55 MACCE 55 Score DAS# 55 serologically active patients 55 aminotransferase elevations greater 55 NIHSS 55 #.#/#.# mmHg [001] 55 EXJADE 55 postoperative AF 55 HAMD 55 #mg/day [001] 55 NYHA class 55 mg TID 55 AGILECT ® 55 prodromal symptoms 55 ventricular fibrillation VF 55 pulmonary vascular 55 hours postdose 55 renal dysfunction 55 baseline HbA1c 55 FFNS 55 postop 55 thromboembolic events 55 hypoventilation 55 bronchospasm 55 akathisia 55 certolizumab 55 stable angina 55 TEAEs 55 pericardial effusions 55 glycated hemoglobin levels 55 anemia hemoglobin 55 primidone 55 airway hyperresponsiveness 55 HRQOL 55 CFQ R 55 #.#mmHg 55 systolic dysfunction 55 dopaminergic therapy 55 aspartate aminotransferase 55 REYATAZ r arm 55 fever headache muscle aches 55 comorbid conditions 55 nausea vomiting constipation 55 muscle aches fatigue 55 poststroke 55 ipsilateral stroke 55 severe neutropenia 55 Primary endpoints 55 Secondary efficacy endpoints 55 parkinsonism 55 arterial thromboembolic events 55 clinically meaningful improvements 55 composite endpoint 55 concomitant medications 55 iloprost 55 nondiabetic patients 55 fatigue abdominal pain 55 asthenia fatigue 55 definite stent thrombosis 55 constipation dizziness 55 elevated ALT 55 somnolence sleepiness 55 reinfarction 55 QTcF 55 hyperreflexia 55 Disease Activity 55 hypoglycemic events 55 lung function 55 laxation 55 MetS 55 8mg/kg 55 Secondary endpoints include 55 subclinical hypothyroidism 55 IPSS 55 Postoperative 55 echocardiographic parameters 55 quetiapine 55 abciximab 55 fatigue shortness 55 Adverse events 55 exertional dyspnea 55 erythrocyte sedimentation rate 55 inotropic 55 transaminase elevations 55 hypercalcemia 55 salivary cortisol 55 vasospasm 55 % CI #.#-#.# [003] 55 rizatriptan 55 cytopenias 55 pulmonary exacerbations 55 creatinine clearance 55 etanercept 55 nasal polyposis 55 hepatomegaly 55 secondary endpoint 55 postoperative 55 Unified Parkinson Disease 55 sleepiness nausea 55 nonfatal myocardial infarction 55 clinically meaningful reductions 55 headache nausea 55 vomiting drowsiness 55 μg dose 55 headache somnolence 55 linaclotide treated 55 postintervention 55 ‰ ¥ 55 FluCAM arm 54 ALT flares 54 depressive symptoms 54 CCyR 54 induration 54 ascites 54 urge incontinence 54 virologic breakthrough 54 metabolic alkalosis 54 AST ALT 54 nocturnal awakenings 54 stridor 54 dyspepsia 54 thrombophlebitis 54 sulfasalazine 54 hallucinations dyskinesia 54 headache chills 54 airway inflammation 54 QTc 54 hematuria 54 IRLS score 54 HAM D# scores 54 MMSE scores 54 ventilatory 54 postoperative nausea 54 pooled comparator 54 MMSE score 54 diaphoresis 54 ALT elevations 54 recurrent genital herpes 54 QD dosing 54 preoperatively 54 mild renal insufficiency 54 anticholinergics 54 hyperglycemia 54 glycemia 54 ileus 54 preoperative 54 insulin detemir 54 QoL 54 mg d 54 perineal pain 54 left ventricular dysfunction 54 mucosal healing 54 International Prostate Symptom 54 dysarthria 54 generalized tonic clonic seizures 54 CDAI score 54 genotypic resistance 54 diarrhea nausea vomiting 54 mg dose 54 bronchodilation 54 neutropenia 54 mg BID dose 54 affective psychosis 54 mg/m2 dose 54 cytopenia 54 neurologic dysfunction 54 Erythropoietic therapies may 54 febrile illness 54 CR nPR 54 recurrent venous thromboembolism 54 elevated creatinine 54 nadroparin 54 refractory ischemia 54 left ventricular diastolic 54 ADHF 54 PREZISTA r 54 receiving VELCADE 54 mg ustekinumab 54 OSAHS 54 mg kg dose 54 nausea somnolence 54 LUTS 54 myoclonus 54 serum urate 54 nonfatal myocardial infarction MI 54 IIIa inhibitor 54 pyridostigmine 54 QTc prolongation 54 reflux symptoms 54 daytime somnolence 54 constipation diarrhea 54 dactylitis 54 mitoxantrone 54 methotrexate monotherapy 54 PANSS total 54 insomnia somnolence 54 confidence interval #.#-#.# 54 hypoperfusion 54 diastolic BP 54 angina pectoris 54 subsyndromal 54 HbA1c levels 54 proteinuria 54 musculoskeletal pain 54 diarrhea flatulence 54 diarrhea abdominal pain 54 dysesthesia 54 6MWD 54 FOLPI 54 beclomethasone dipropionate 54 biphasic insulin aspart 54 morphometric vertebral fractures 54 ADCS ADL 54 expiratory 54 edema 54 fatigue nausea vomiting 54 moderate renal impairment 54 receiving VICTRELIS 54 hemorrhagic complications 54 Severity Index PASI 54 DAS# CRP 54 APTIVUS r 54 pyrexia mucositis sepsis febrile 54 concomitant AEDs 54 tranylcypromine 54 dizziness somnolence 54 aspartate aminotransferase AST 54 abdominal pain nausea 53 ARIXTRA 53 events TEAEs 53 serum ALT 53 cerebral perfusion 53 breathlessness 53 reintubation 53 electrolyte abnormalities 53 included neutropenia anemia 53 enthesitis 53 gastroduodenal 53 Forced expiratory volume 53 sUA 53 depressive symptomatology 53 ml kg 53 myocardial infarction stroke 53 serum cortisol 53 tipranavir r 53 mm Hg systolic 53 headache myalgia 53 dyslipidaemia 53 antihypertensive therapy 53 coagulopathy 53 budesonide formoterol 53 systolic BP 53 myopathy rhabdomyolysis 53 airflow limitation 53 mg/# h 53 cirrhotic patients 53 corticosteroid dose 53 diabetic gastroparesis 53 TNSS 53 hyperphenylalaninemia HPA due 53 colorectal adenoma 53 bloating abdominal pain 53 parkinsonian 53 daytime alertness 53 acid regurgitation 53 CR CRu 53 urge urinary incontinence 53 systemic corticosteroids 53 metabolic acidosis 53 secondary efficacy endpoint 53 perioperatively 53 angina chest 53 mm Hg 53 μmol L 53 postoperative complication 53 aminotransferases 53 non menstrual pelvic 53 Score DAS 53 Key secondary endpoints 53 lung edema 53 comorbid depression 53 abdominal pain diarrhea 53 QVAR R 53 vomiting nausea 53 trough FEV1 53 Scale EDSS score 53 LAMICTAL 53 subscale scores 53 hypervolemic 53 6R BH4 53 diarrhea abdominal 53 p = .# [001] 53 post thrombotic syndrome 53 AGILECT R 53 neurologic complications 53 diarrhea constipation 53 systolic hypertension 53 peak VO2 53 severe hypoglycemia 53 syndrome OSAS 53 VAPRISOL 53 APACHE II 53 hemodynamic instability 53 serum potassium 53 neutropenia anemia 53 Inventory BPI 53 hemodynamic parameters 53 nausea vomiting dizziness 53 mild renal impairment 53 pulmonary infiltrates 53 induce orthostatic hypotension 53 alanine aminotransferase ALT 53 NYHA Class II 53 atrophic gastritis 53 generalized seizures 53 #mg BID [003] 53 symptom exacerbation 53 recurrent wheezing 53 candesartan 53 depressive symptom 53 lamotrigine 53 upper gastrointestinal bleeding 53 cyanosis 53 Symptom severity 53 NIHSS score 53 Y BOCS 53 chills fever 53 angioneurotic edema 53 virologic response 53 hyperactivity impulsivity 53 heparin induced thrombocytopenia 53 bacteremia 53 neuropsychiatric symptoms 53 Exacerbations 53 ribavirin therapy 53 dyskinesia 53 hypervolemic hyponatremia 53 oral prednisolone 53 angiotensin converting enzyme inhibitors 53 peripheral neuropathy 53 somnolence 53 CONCERTA ® 53 idiopathic Parkinson disease 53 lactic acidosis 53 Hb A1C 53 nonoperative treatment 53 REMICADE ® 53 chronic cough 53 decrements 53 placebo fluoxetine 53 moderately emetogenic 53 hemodynamics 53 spinal cord compression 53 NPH insulin 53 radicular pain 53 rectal bleeding 53 activated partial thromboplastin 53 chronic thromboembolic pulmonary 53 unresectable HCC 53 ADAS Cog 53 IBS C 53 triamcinolone 53 Abdominal pain 53 5-FU/LV 53 dizziness lightheadedness 53 cardiac ischemia 53 ug kg 53 statistically significant reduction 53 infection nasopharyngitis 53 antiarrhythmic drug 53 Global Impression CGI 53 muscle aches headache 53 cardiac dysfunction 53 oral corticosteroids 53 #mg BID [001] 53 LEXIVA r 53 certolizumab pegol 53 CTEPH 53 bronchoconstriction 53 diastolic dysfunction 53 binary restenosis 53 urinary retention 53 LV dysfunction 53 IRLS 53 posttransplant 53 divalproex 53 Health Assessment Questionnaire 53 muscle rigidity 53 mg tid 53 pruritus itching 53 LV ejection fraction 53 salmeterol inhalation powder 53 OADs 53 adjunctive placebo 53 superficial edema 53 atopic 53 Nausea vomiting 53 nephrotoxicity 53 hemoglobin A1c HbA1c 53 infusion reactions 53 Thrombolysis 53 titrated glipizide 53 Hypersensitivity reactions 53 photophobia 53 #mg/day [002] 53 proctitis 53 CPAP adherence 53 esophageal carcinoma 53 lipid parameters 53 jugular venous 53 ADCS CGIC 53 macrovascular disease 52 diarrhea vomiting rash 52 nasal congestion sore throat 52 mcg kg 52 oral antidiabetic medication 52 CIMZIA TM 52 hyperammonemia 52 vomiting abdominal pain 52 gastrointestinal disturbances 52 DETROL LA 52 coronary revascularization 52 revascularization procedures 52 neurodevelopmental impairment 52 Apidra ® 52 intravitreal injections 52 residual platelet reactivity 52 teriflunomide 52 metabolic parameters 52 unstable angina pectoris 52 dizziness headache 52 comorbidities 52 fasting plasma glucose FPG 52 tertile 52 TMP SMX 52 acneform rash 52 nonsignificant 52 comorbid 52 DLTs 52 nausea headache 52 anterior uveitis 52 fractional shortening 52 FOLFOX 52 rosuvastatin #mg 52 ACEIs 52 bradykinesia 52 p = 52 HbA 1C 52 preintervention 52 decompensation 52 hepatic encephalopathy 52 INVEGA ® 52 virological failure 52 constipation OIC 52 BYSTOLIC 52 Depressive symptoms 52 vertigo dizziness 52 aortic regurgitation 52 symptomatic intracranial 52 potassium sparing diuretics 52 -#.# mg dL [002] 52 quetiapine XR 52 knee osteoarthritis OA 52 IELT 52 urinary albumin 52 atopic asthma 52 PASI scores 52 postprandial glucose 52 Oral corticosteroids 52 CIMZIA ™ 52 corticosteroid therapy 52 #mg doses [002] 52 disordered breathing 52 treatment emergent AEs 52 extubation 52 Neuropsychiatric Inventory NPI 52 montelukast 52 splenectomized 52 adverse reactions ≥ 52 budesonide pMDI 52 QTc intervals 52 lymphadenopathy 52 clomipramine 52 syncopal 52 hematological toxicity 52 parkinsonian symptoms 52 Hypotension 52 ziprasidone 52 ARICEPT 52 abdominal pain 52 SCr 52 vomiting PONV 52 prodrome 52 coughing sore throat 52 obstructive apnea 52 spirometric 52 runny nose nasal congestion 52 serum sodium 52 UA NSTEMI 52 insomnia nausea 52 Januvia ® 52 nasal stuffiness 52 % CI #.#-#.# [004] 52 adjunctive ABILIFY 52 anastomotic leak 52 atherogenic dyslipidemia 52 fever headache nausea 52 shortness 52 carotid stenosis 52 Apgar scores 52 Scale EDSS 52 artery stenosis 52 dapagliflozin plus 52 abdominal cramping 52 tolterodine 52 mm Hg diastolic 52 subcutaneous insulin 52 alteplase 52 recurrent VTE 52 AUC0 52 dizziness headache nausea 52 hypertensives 52 #mg QD [002] 52 prespecified secondary 52 nausea vomiting diarrhea abdominal 52 acute exacerbations 52 creatine phosphokinase 52 microvascular complications 52 euvolemic 52 tachypnea 52 sweating nausea 52 tegaserod 52 infarct size 52 sinus bradycardia 52 hyperalgesia 52 EDSS scores 52 adalimumab 52 evaluable subjects 52 echocardiographic 52 headache nausea dizziness 52 light headedness dizziness 52 diabetes mellitus DM 52 rotigotine 52 FEV1 forced expiratory 52 μg kg 52 PsA 52 emesis 52 amisulpride 52 milrinone 52 icatibant 52 thrombocytopenic 52 ventricular tachyarrhythmia 52 Raynaud phenomenon 52 peripheral neuropathy aggravated 52 aripiprazole 52 Fasting plasma glucose 52 QTc interval 52 exploratory endpoints 52 FOLFOX4 52 n = 52 serum phosphorous 52 oral anticoagulant therapy 52 CI #.#-#.# [001] 52 abdominal pain bloating 52 systolic function 52 mucositis 52 partial remissions 52 pCR 52 dobutamine 52 co morbidities 52 pulmonary artery banding 52 amoxicillin clavulanate 52 inflammatory lesions 52 DOXIL 52 sustained ventricular tachycardia 52 anemia nausea 52 fasting plasma glucose 52 palpitations shortness 52 headache nausea diarrhea 52 EQ 5D 52 HF hospitalization 52 intermittent dosing 52 abdominal pain diarrhea nausea 52 divalproex sodium 52 pegylated interferon alfa 2b 52 dysphoric 52 MCyR 52 corrected QT interval 52 euthymic 52 #.#mg/dL 52 Cheyne Stokes 52 runny nose headache 52 AVANDIA 52 nausea vomiting cramps 52 cough wheeze 52 nonhematologic adverse reactions 52 peginterferon alfa 2a 52 Visual Analog Scale 52 hyperintense lesions 52 achieved PASI 52 mmHg diastolic 52 secondary endpoints 52 nonfatal stroke 52 F FDG PET 52 urinary frequency 52 p = #.# [003] 52 occlusive disease 52 Tasigna prolongs 52 statistically significant p 52 pouchitis 52 LPV r 52 serum phosphate levels 52 systemic hypotension 52 dizziness sleepiness 52 Neutropenia 52 postural hypotension 52 EDARBI 52 aldosterone antagonists 52 nadolol 52 splenomegaly 52 glomerular filtration 52 anticholinergic agents 52 neutropenic patients 52 procedural sedation 52 cerebral infarction 52 Index CDAI score 52 electrical cardioversion 52 arterial oxygen saturation 52 Expanded Disability Status 52 timepoint 52 respiratory symptoms 52 fever headaches nausea 52 thrombocytopenia anemia 52 anticholinergic medication 52 oral corticosteroid 52 EDSS 52 ruboxistaurin 52 creatinine ratio 51 hemorrhagic cystitis 51 Nocturia 51 wheezing breathlessness 51 reflux esophagitis 51 Negative Syndrome 51 Daytime sleepiness 51 #OHD 51 hematological adverse 51 p ≤ 51 Pain Intensity 51 gout flare 51 mcg kg REBETOL 51 headache dizziness 51 PLMs 51 progression TTP 51 hyperlipidaemia 51 severe renal impairment 51 abdominal pain constipation 51 intravenous vancomycin 51 torsade de pointes 51 opioid analgesia 51 VT VF 51 abdominal pain vomiting 51 Rating Scale UPDRS 51 CrCl 51 hypersensitivity reaction 51 upper airway obstruction 51 colic diarrhea 51 placebo dexamethasone 51 antimuscarinic 51 q#h 51 salmeterol fluticasone propionate 51 maximal treadmill 51 corticosteroids immunoglobulins 51 #mg/m# [001] 51 anaphylactic reactions bronchospasm 51 levetiracetam 51 Chronic cough 51 serum creatinine levels 51 coronary stenosis 51 QIDS SR 51 comparator arm 51 urinary sodium excretion 51 chlorambucil 51 bortezomib refractory 51 pheochromocytoma 51 BMI ≥ 51 hepatotoxicity 51 biochemical relapse 51 paroxysmal AF 51 analgesia 51 esophageal reflux 51 RBC transfusion 51 lacosamide 51 SpO 2 51 esophagitis 51 periprocedural 51 elevated transaminases 51 angina 51 vasopressor 51 status epilepticus 51 ALT elevation 51 BPS IC 51 vitreous floaters